reports
Novo Nordisk AS: 1 director
A director at Novo Nordisk AS sold 40,000 shares at 450.528DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
- Rune Majlund Dahl
Zealand Pharma (Buy, TP: DKK950.00) - Dapiglutide likely next catalyst
Q1 revenue missed expectations on lower reimbursement revenue, while operating profit was a beat, as opex was below our forecast and consensus. The 2025 guidance was maintained for opex of DKK2,000m–2,500m. We believe the next potential share-price catalyst is the top-line results from the phase Ib dapiglutide trial in Q2e. We reiterate our BUY, but have cut our target price to DKK950 (1,000).
- Rune Majlund Dahl
Novo Nordisk (Buy, TP: DKK900.00) - Accelerated Wegovy roll-out ahead
Q1 LCY figures beat our forecasts, while the 2025 guidance was cut to 13–21% LCY sales growth YOY and 16–24% LCY operating profit growth YOY due to weaker GLP-1 sales. We have lowered our rebate for US Ozempic but maintain our 52% Wegovy rebate (in line with the Q1 rebate when adjusting for de-stocking). We reiterate our BUY and DKK900 target price.
Husqvarna AB: 2 directors
Two Directors at Husqvarna AB bought 1,104,792 shares at between 44.920SEK and 45.175SEK. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- Lara Mohtadi
VOLV B VOLVO AB CLASS B
WRT1V WARTSILA OYJ ABP
ABB ABB LTD.
SAND SANDVIK AB
TREL B TRELLEBORG AB CLASS B
MOCORP METSO OUTOTEC OYJ
ASSA B ASSA ABLOY AB CLASS B
SKF B SKF AB CLASS B
ALFA ALFA LAVAL AB
MTRS B MUNTERS GROUP
HEXA B HEXAGON AB
EPI A EPIROC AB
NIBE B NIBE INDUSTRIER AB
ATCO A ATLAS COPCO AB
ALIV SDB AUTOLIV INC.
ROCKWOOL A/S – transaktioner i henhold til aktietilbagekøbsprogram
ROCKWOOL A/S – transaktioner i henhold til aktietilbagekøbsprogram Selskabsmeddelelsefor ROCKWOOL A/SMeddelelse nr. 28 – 2025til Nasdaq Copenhagen 7. maj 2025 ROCKWOOL A/S – transaktioner i henhold til aktietilbagekøbsprogram Som meddelt i selskabsmeddelelse nr. 07/2025 har ROCKWOOL A/S iværksat et aktietilbagekøbsprogram, som løber i perioden fra og med 7. februar 2025 og til og med den 5. februar 2026. I denne periode vil Selskabet købe egne aktier for op til maksimalt 150 mio. euro. Tilbagekøbsprogrammet gennemføres i henhold til EU-Kommissionens forordning nr. 596/2014 af 16...
ROCKWOOL A/S – transactions in connection with share buy-back programm...
ROCKWOOL A/S – transactions in connection with share buy-back programme Company announcementfor ROCKWOOL A/SRelease no. 28 – 2025to Nasdaq Copenhagen 7 May 2025 ROCKWOOL A/S – transactions in connection with share buy-back programme As mentioned in announcement no. 07/2025, ROCKWOOL A/S has initiated a share buy-back programme which will run from 7 February 2025 until 5 February 2026. During this period, the Company will buy own shares for up to a maximum of 150 MEUR. The programme is implemented in accordance with EU Commission Regulation No 596/2014 of 16 April 2014 and EU Com...
Nedsættelse af aktiekapitalen
Nedsættelse af aktiekapitalen Selskabsmeddelelsefor ROCKWOOL A/SMeddelelse nr. 27 – 2025til Nasdaq Copenhagen 2. maj 2025 Nedsættelse af aktiekapitalen På den ordinære generalforsamling i ROCKWOOL A/S (”Selskabet”) den 2. april 2025 blev det besluttet at nedsætte Selskabets B-aktiekapital fra nominelt 118.028.700 DKK til nominelt 113.427.400 DKK ved annullering af en del af Selskabets beholdning af egne B-aktier, i alt nominelt 4.601.300 DKK. Selskabet har i dag registreret kapitalnedsættelsens gennemførelse hos Erhvervsstyrelsen og dermed annulleret 4.601.300 B-aktier á 1 DKK s...
Reduction of the share capital
Reduction of the share capital Company announcementfor ROCKWOOL A/SRelease no. 27 – 2025to Nasdaq Copenhagen 2 May 2025 Reduction of the share capital At the Annual General Meeting of ROCKWOOL A/S (the “Company”) held on 2 April 2025, it was resolved to reduce the Company’s B share capital from nominally 118,028,700 DKK to nominally 113,427,400 DKK by cancelling a portion of the Company’s treasury B shares, corresponding to nominally 4,601,300 DKK. The Company has today completed the capital reduction and registered it with the Danish Business Authority, thus cancelling 4,601,30...
- Rune Majlund Dahl
Novo Nordisk (Buy, TP: DKK900.00) - Underlying soft GLP-1 sales
We forecast a soft Q1, with 17.3% LCY sales growth and 13.8% LCY operating profit growth due to subdued prescriptions. While we estimate Ozempic sales c0.5% below consensus, we are c1.2% above for Wegovy, as we include DKK1bn in sales related to Wegovy US inventories. We see likely relief from potential unchanged 2025 LCY guidance, supported by improved Wegovy supply and fading pressure from compounders. We reiterate our BUY and DKK900 target price.
Samlet antal aktier og stemmerettigheder i ROCKWOOL A/S
Samlet antal aktier og stemmerettigheder i ROCKWOOL A/S Selskabsmeddelelsefor ROCKWOOL A/SMeddelelse nr. 26 – 2025til Nasdaq Copenhagen 30. april 2025 Samlet antal aktier og stemmerettigheder i ROCKWOOL A/S ROCKWOOL A/S (”Selskabet”) gennemførte den 11. april 2025 et aktiesplit i forholdet 1:10 i henhold til beslutning truffet på Selskabets ordinære generalforsamling den 2. april 2025. I henhold til § 32 i kapitalmarkedsloven er Selskabet forpligtet til at offentliggøre det samlede antal stemmerettigheder og aktier i tilfælde af ændringer. Efter gennemførelsen af aktiesplittet u...
Total number of shares and voting rights in ROCKWOOL A/S
Total number of shares and voting rights in ROCKWOOL A/S Company announcementfor ROCKWOOL A/SRelease no. 26 – 2025to Nasdaq Copenhagen 30 April 2025 Total number of shares and voting rights in ROCKWOOL A/S ROCKWOOL A/S (“the Company”) completed a share split in the ratio of 1:10 on 11 April 2025 pursuant to a resolution adopted at the Company’s Annual General Meeting on 2 April 2025. In accordance with Section 32 of the Danish Capital Market Act, the Company is required to disclose the total number of voting rights and shares in the event of changes. Following completion of the ...
ROCKWOOL A/S – transaktioner i henhold til aktietilbagekøbsprogram
ROCKWOOL A/S – transaktioner i henhold til aktietilbagekøbsprogram Selskabsmeddelelsefor ROCKWOOL A/SMeddelelse nr. 25 – 2025til Nasdaq Copenhagen 30. april 2025 ROCKWOOL A/S – transaktioner i henhold til aktietilbagekøbsprogram Som meddelt i selskabsmeddelelse nr. 07/2025 har ROCKWOOL A/S iværksat et aktietilbagekøbsprogram, som løber i perioden fra og med 7. februar 2025 og til og med den 5. februar 2026. I denne periode vil Selskabet købe egne aktier for op til maksimalt 150 mio. euro. Tilbagekøbsprogrammet gennemføres i henhold til EU-Kommissionens forordning nr. 596/2014 af...
ROCKWOOL A/S – transactions in connection with share buy-back programm...
ROCKWOOL A/S – transactions in connection with share buy-back programme Company announcementfor ROCKWOOL A/SRelease no. 25 – 2025to Nasdaq Copenhagen 30 April 2025 ROCKWOOL A/S – transactions in connection with share buy-back programme As mentioned in announcement no. 07/2025, ROCKWOOL A/S has initiated a share buy-back programme which will run from 7 February 2025 until 5 February 2026. During this period, the Company will buy own shares for up to a maximum of 150 MEUR. The programme is implemented in accordance with EU Commission Regulation No 596/2014 of 16 April 2014 and EU ...
- Rune Majlund Dahl
Zealand Pharma (Buy, TP: DKK1000.00) - Focus on pipeline progression
We expect an uneventful Q1 report, with investor focus on top-line results from the dapiglutide phase Ib obesity trial (due in Q2), which could help provide clarity on the positioning of the molecule in obesity and inflammation. For petrelintide, we have reduced our peak sales forecast to cUSD10.0bn (cUSD10.8bn) on increased competition from GUBamy. We reiterate our BUY but have cut our target price to DKK1,000 (1,150).
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- Mattias Holmberg
Epiroc (Hold, TP: SEK220.00) - Solid equipment demand
A solid Q1 report included orders and sales up 10% and 3% organically YOY, respectively, and an adj. EBIT margin of 19.9%; however, this included a 190bp FX boost, and we believe underlying margins could remain under pressure until the service mix improves. Albeit with increased uncertainty, management guided for mining demand to remain strong but construction to remain weak near-term. We have trimmed our 2025–2027e sales and adj. EBIT by 2% (FX-related) but reiterate our HOLD and SEK220 target ...
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- ABGSC Construct. & Real Estate Research
- Fredrik Stensved
- Markus Henriksson
- Oscar Lindquist
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.